QS Investors LLC grew its position in Exelixis, Inc. (NASDAQ:EXEL) by 95.8% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 15,540 shares of the biotechnology company’s stock after purchasing an additional 7,602 shares during the period. QS Investors LLC’s holdings in Exelixis were worth $383,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. FMR LLC raised its holdings in Exelixis by 2.0% in the second quarter. FMR LLC now owns 43,748,695 shares of the biotechnology company’s stock worth $1,077,530,000 after purchasing an additional 857,452 shares during the period. Vanguard Group Inc. increased its position in shares of Exelixis by 7.2% during the second quarter. Vanguard Group Inc. now owns 25,441,964 shares of the biotechnology company’s stock worth $626,635,000 after acquiring an additional 1,706,893 shares in the last quarter. Meditor Group Ltd increased its position in shares of Exelixis by 5.5% during the second quarter. Meditor Group Ltd now owns 20,229,713 shares of the biotechnology company’s stock worth $498,258,000 after acquiring an additional 1,046,000 shares in the last quarter. BlackRock Inc. increased its position in shares of Exelixis by 33,678.5% during the first quarter. BlackRock Inc. now owns 19,155,466 shares of the biotechnology company’s stock worth $415,099,000 after acquiring an additional 19,098,757 shares in the last quarter. Finally, State Street Corp increased its position in shares of Exelixis by 2.1% during the first quarter. State Street Corp now owns 7,710,338 shares of the biotechnology company’s stock worth $167,087,000 after acquiring an additional 157,199 shares in the last quarter. Institutional investors own 78.40% of the company’s stock.
EXEL has been the subject of several research reports. TheStreet raised shares of Exelixis from a “c” rating to a “b-” rating in a research report on Monday, August 7th. SunTrust Banks, Inc. initiated coverage on shares of Exelixis in a research report on Thursday, July 13th. They set a “buy” rating and a $33.00 price objective for the company. BidaskClub downgraded shares of Exelixis from a “strong-buy” rating to a “buy” rating in a research report on Monday, August 14th. Piper Jaffray Companies reissued a “buy” rating and set a $29.00 price objective on shares of Exelixis in a research report on Thursday, August 3rd. Finally, Needham & Company LLC reissued a “buy” rating and set a $30.00 price objective (up previously from $28.00) on shares of Exelixis in a research report on Tuesday, September 12th. Six investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Exelixis presently has a consensus rating of “Buy” and an average price target of $31.38.
In other Exelixis news, VP Patrick J. Haley sold 60,640 shares of the company’s stock in a transaction on Thursday, September 14th. The shares were sold at an average price of $27.21, for a total transaction of $1,650,014.40. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Christopher J. Senner sold 100,000 shares of the company’s stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $26.79, for a total transaction of $2,679,000.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 970,152 shares of company stock worth $25,923,457. Corporate insiders own 5.10% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “QS Investors LLC Boosts Position in Exelixis, Inc. (EXEL)” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2017/10/28/exelixis-inc-exel-shares-bought-by-qs-investors-llc.html.
Exelixis, Inc. (EXEL) opened at 26.63 on Friday. Exelixis, Inc. has a 52-week low of $10.04 and a 52-week high of $32.50. The company has a 50-day moving average of $26.15 and a 200-day moving average of $24.29. The company has a market cap of $7.83 billion, a P/E ratio of 134.49 and a beta of 1.91.
Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported $0.06 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.04 by $0.02. Exelixis had a net margin of 18.20% and a return on equity of 80.43%. The firm had revenue of $99.01 million for the quarter, compared to the consensus estimate of $85.27 million. During the same quarter in the prior year, the company posted ($0.15) earnings per share. The business’s revenue was up 173.1% on a year-over-year basis. On average, equities research analysts expect that Exelixis, Inc. will post $0.28 earnings per share for the current fiscal year.
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
Receive News & Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.